Table 1. Baseline Characteristics of Study Communities Measured in the Baseline Census.
| Characteristic | Azithromycin | Placebo |
|---|---|---|
| No. (%) of communitiesa | 144 | 140 |
| No. (%) of HDSS communitiesb | 23 (16.0) | 18 (12.9) |
| No. of children | 22 148 | 22 639 |
| No. (%) of children in HDSS | 3295 (14.9) | 2599 (11.5) |
| No. of children per community, median (IQR) | 146 (85-210) | 148 (96-226) |
| Child’s sex, No. (%) | ||
| Female | 10 883 (49.1) | 11 249 (49.7) |
| Male | 11 265 (50.9) | 11 390 (50.3) |
| Age group, No. (%) | ||
| 1-11 mo | 3606 (16.3) | 3580 (15.8) |
| 12-23 mo | 4575 (20.7) | 4709 (20.8) |
| 24-59 mo | 13 967 (63.1) | 14 350 (63.4) |
| Mid-upper arm circumference, median (IQR), cm | 14.6 (14.0-15.5) | 14.5 (3.8-15.3) |
Abbreviation: HDSS, health and demographic surveillance site.
a
Number of communities measured at the baseline census; 27 communities in the azithromycin group and 30 communities in the placebo group were not measured in the baseline census due to security concerns.
b
Randomization was stratified by whether the study community fell within an existing HDSS and were selected for additional morbidity monitoring. The HDSS has been conducting population-based surveillance and monitoring since 1992 and a subset of the trial’s communities were part of the HDSS.